Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Akili Interactive Labs
Thumbnail
March 01, 2022

The uncertain future of medtech Spac deals

Thumbnail
January 26, 2022

Akili plays the Spac game for $1bn

But, judging by similar transactions, the valuation might not stay that high for long.

Article image
Vantage logo
September 29, 2021

Akili and Shionogi find the clinical game hard to play

Article image
Vantage logo
August 17, 2021

How long will the good times roll for medtech?

The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.

Article image
Vantage logo
July 09, 2021

Medtech venture funding hits new heights

Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.

Article image
Vantage logo
December 03, 2020

Prescription apps take off during lockdown

Digital therapeutics are going from strength to strength during the pandemic.

Article image
Vantage logo
June 16, 2020

Akili’s therapeutic computer game snares world-first approval

Article image
Vantage logo
February 25, 2020

Akili hopes the FDA pays attention

Article image
Vantage logo
October 31, 2019

One step forward, two steps back for prescription apps

Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.

Article image
Vantage logo
August 15, 2019

Digital therapeutics have potential but commercial success unproven

Software can be a medical device. Can it also be a drug?

Vantage logo
May 11, 2018

Snippet roundup: Pivotal fluffs from Faron and Fasenra

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.